| 1 |
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine
Open access |
4 Jun 2018 |
3,816 |
| 2 |
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
3,488 |
| 3 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al. · New England Journal of Medicine
Open access |
21 Apr 2021 |
1,671 |
| 4 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 5 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al. · The Lancet Oncology
Open access |
28 Nov 2016 |
1,218 |
| 6 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology
|
12 Apr 2015 |
967 |
| 7 |
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al. · The Lancet Respiratory Medicine
|
26 Mar 2019 |
954 |
| 8 |
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
18 Aug 2021 |
792 |
| 9 |
Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer
Sami Diab · JNCI Journal of the National Cancer Institute
|
5 Apr 2000 |
680 |
| 10 |
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al. · Clinical Cancer Research
Open access |
15 Feb 2009 |
666 |
| 11 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood
Open access |
4 Mar 2014 |
646 |
| 12 |
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor O. Vynnychenko et al. · Journal of Thoracic Oncology
Open access |
14 Apr 2020 |
618 |
| 13 |
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
William D. Tap et al. · New England Journal of Medicine
|
29 Jul 2015 |
593 |
| 14 |
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T. Tagawa, Arjun Vasant Balar, Daniel Peter Petrylak et al. · Journal of Clinical Oncology
Open access |
30 Apr 2021 |
553 |
| 15 |
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology
Open access |
24 Jul 2021 |
546 |
| 16 |
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew Hiram Taylor, Carol A Aghajanian et al. · Journal of Clinical Oncology
Open access |
13 Mar 2020 |
531 |
| 17 |
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana Kehr Ellis, Henry G. Bone, Rowan T. Chlebowski et al. · Journal of Clinical Oncology
|
25 Aug 2008 |
484 |
| 18 |
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker, Drew Warren Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology
Open access |
26 Mar 2019 |
482 |
| 19 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kunnathu Kumar, Ian W. Flinn, Paul Gerard Guy Richardson et al. · Blood
|
16 Mar 2012 |
453 |
| 20 |
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
A. Ashworth, Suresh Senan, David A. Palma et al. · Clinical Lung Cancer
|
15 May 2014 |
439 |
| 21 |
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Jennifer Keating Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology
Open access |
20 Aug 2020 |
412 |
| 22 |
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark J. Roschewski, Michail S. Lionakis, Jeff Porter Sharman et al. · Science Immunology
Open access |
5 Jun 2020 |
380 |
| 23 |
Palliative Care for Patients With Cancer: ASCO Guideline Update
Justin J. Sanders, Sarah Temin, Arunangshu Ghoshal et al. · Journal of Clinical Oncology
Open access |
15 May 2024 |
352 |
| 24 |
Evaluation of cell-free DNA approaches for multi-cancer early detection
Arash Jamshidi et al. · Cancer Cell
Open access |
17 Nov 2022 |
335 |
| 25 |
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami et al. · Journal of Thoracic Oncology
Open access |
7 Oct 2021 |
313 |
| 26 |
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven Peter Treon, Leukothea Ioakimidis, Jacob Drobnyk Soumerai et al. · Journal of Clinical Oncology
Open access |
9 Jun 2009 |
294 |
| 27 |
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al. · Gynecologic Oncology
Open access |
4 Sep 2017 |
282 |
| 28 |
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology
|
3 Mar 2009 |
276 |
| 29 |
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
Richard A. Nash et al. · Blood
Open access |
24 Apr 2007 |
265 |
| 30 |
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey Howard Lipton et al. · The Lancet Oncology
|
12 Apr 2016 |
264 |
| 31 |
Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
Mohamed Lotfy Sorror, Barry E. Storer, Brenda M. Sandmaier et al. · Cancer
Open access |
29 Feb 2008 |
264 |
| 32 |
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al. · The Lancet Haematology
Open access117 authors |
18 Jul 2019 |
249 |
| 33 |
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
David Michael Waterhouse et al. · Journal of Clinical Oncology
Open access |
10 Sep 2020 |
247 |
| 34 |
Safety and Efficacy of 68 Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
Stephen A. Deppen, Eric Liu, Jeffrey D. Blume et al. · Journal of Nuclear Medicine
Open access |
14 Jan 2016 |
237 |
| 35 |
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology
Open access |
6 Mar 2018 |
230 |
| 36 |
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
Hillel P. Cohen, Andrew Blauvelt, Robert M. Rifkin et al. · Drugs
ReviewOpen access |
Mar 2018 |
222 |
| 37 |
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al. · Nature Communications
Open access |
3 May 2021 |
209 |
| 38 |
Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin.
Joëlle Roche, Ferenc L. Boldog, Misi Robinson et al. · PubMed
|
21 Mar 1996 |
195 |
| 39 |
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · JAMA Oncology
Open access |
16 Feb 2023 |
193 |
| 40 |
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David Robert Spigel et al. · Journal of Thoracic Oncology
Open access |
20 May 2019 |
190 |
| 41 |
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Chung‐Han Lee et al. · The Lancet Oncology
Open access |
15 Jun 2021 |
189 |
| 42 |
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
Steven Peter Treon, Zachary R. Hunter, Jeffrey Matous et al. · Clinical Cancer Research
|
Jun 2007 |
188 |
| 43 |
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia
HA Drabkin, C Parsy, Kevin L. Ferguson et al. · Leukemia
|
Feb 2002 |
187 |
| 44 |
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
Robert M. Jotte, Paul Conkling, Craig H. Reynolds et al. · Journal of Clinical Oncology
|
7 Dec 2010 |
178 |
| 45 |
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia
Irene M. Ghobrial, Fangxin Hong, Swaminathan Padmanabhan et al. · Journal of Clinical Oncology
Open access |
9 Feb 2010 |
166 |
| 46 |
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan Hale Fowler et al. · Journal of Clinical Oncology
Open access |
8 Mar 2021 |
163 |
| 47 |
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Howard West, Mark L. McCleland, Federico Cappuzzo et al. · Journal for ImmunoTherapy of Cancer
Open access |
Feb 2022 |
155 |
| 48 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel Peter Petrylak et al. · The Lancet Oncology
|
2 Mar 2015 |
151 |
| 49 |
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
Irene M. Ghobrial, Wanling Xie, Swaminathan Padmanabhan et al. · American Journal of Hematology
|
10 Jun 2010 |
150 |
| 50 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
Steven Peter Treon, Andrew Robert Branagan, Leukothea Ioakimidis et al. · Blood
Open access |
18 Nov 2008 |
148 |